Gilead: Fourth Quarter Earnings Overview

Gilead Sciences Announces Strong Fourth-Quarter Results

Gilead Sciences Inc., headquartered in Foster City, California, revealed on Tuesday that it achieved a net profit of $2.18 billion for the fourth quarter.

The company reported earnings of $1.74 per share, with adjusted earnings—excluding special items—reaching $1.86 per share.

These figures surpassed analysts’ forecasts, as the consensus among nine experts polled by Zacks Investment Research anticipated earnings of $1.83 per share.

Gilead, known for its HIV and hepatitis C treatments, also reported quarterly revenue of $7.93 billion, outperforming the $7.57 billion projection from seven Zacks analysts.

Looking ahead, Gilead projects its full-year earnings to fall between $8.45 and $8.85 per share.